drugset / Trial / NCT06015048
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.
Timeline
- Start
- 2023-08-11
- Primary completion
- 2026-11
- Completion
- 2026-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |
| Background | Pyrotinib | Small molecule | — | — |
Indications
No indication recorded.